Benitec Biopharma Inc.
BNTC
$14.61
-$0.33-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -94.44% |
| SG&A Expenses | 166.67% | 93.97% | 42.23% | 48.50% | 28.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 146.03% | 24.30% | -1.41% | 21.75% | -5.78% |
| Operating Income | -146.03% | -24.30% | 1.41% | -21.93% | 4.61% |
| Income Before Tax | -118.60% | -8.22% | 15.03% | -1.27% | 2.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -118.60% | -8.22% | 15.03% | -1.27% | 2.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.60% | -8.22% | 15.03% | -1.27% | 2.68% |
| EBIT | -146.03% | -24.30% | 1.41% | -21.93% | 4.61% |
| EBITDA | -147.21% | -24.40% | 1.52% | -21.93% | 4.48% |
| EPS Basic | -3.50% | 87.37% | 84.40% | 78.81% | 91.24% |
| Normalized Basic EPS | -3.55% | 87.37% | 82.78% | 81.27% | 91.23% |
| EPS Diluted | -3.50% | 87.37% | 84.40% | 78.81% | 91.24% |
| Normalized Diluted EPS | -3.55% | 87.37% | 82.78% | 81.27% | 91.23% |
| Average Basic Shares Outstanding | 111.14% | 756.86% | 393.46% | 440.60% | 1,010.69% |
| Average Diluted Shares Outstanding | 111.14% | 756.86% | 393.46% | 440.60% | 1,010.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |